Method for Detecting Liver Diseases
AssigneesThe General Hospital Corporation, President and Fellows of Harvard College
InventorsDavid T. Ting, Irun Bhan, Kelly Mosesso, Martin Aryee
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for diagnosing, determining, or monitoring liver diseases and conditions based on the blood concentration of circulating epithelial cells in and their gene expression.
Claims27
A method, comprising measuring expression levels of hepatocellular carcinoma (HCC) classifier genes in circulating epithelial cells (CECs) of a subject, wherein the HCC classifier genes comprise one or more of TESC, OSBP2, SLC6A8, SEPT5, F2RL3, E2F1, EZH2, CDC20, CCNA2, CCNB1, PLXNB3, CDC6, MYBL2, APOBEC3B, SPP1, AKR1B10, TOP2A, ASPM, SLC6A9, RECQL4, NUSAP1, PLVAP, FMO1, PDZK1IP1, and FBXO32.
A method of distinguishing between the presence of early stage liver fibrosis and late stage liver fibrosis in a subject having CLD, the method comprising:
- (a) detecting a concentration of CECs in a blood sample of the subject;
- (b) comparing the concentration of CECs in the blood sample of the subject with a reference value;
- (c) diagnosing the subject with early stage fibrosis if the subject has concentration of CECs in the blood sample that is below the reference value;
- and
- (d) diagnosing the subject with late stage fibrosis if the subject has concentration of CECs in the blood sample that is above the reference value.
Dependencies are inferred from the claim text.